Comparative Pharmacology
Head-to-head clinical analysis: TOPICORT versus TRIDESILON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TOPICORT versus TRIDESILON.
TOPICORT vs TRIDESILON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid that induces phospholipase A2 inhibitory proteins, collectively called lipocortins, which inhibit the release of arachidonic acid, thereby reducing production of prostaglandins and leukotrienes, leading to anti-inflammatory, antipruritic, and vasoconstrictive effects.
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, collectively called lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid from membrane phospholipids.
Apply a thin film to the affected skin areas twice daily. Maximum adult dose: 50 g/week. Not for use on the face, axillae, or groin. Do not use under occlusive dressings.
0.05% ointment or cream applied topically to affected area twice daily.
None Documented
None Documented
Terminal elimination half-life: 2-4 hours for parent drug; clinical effect lasts longer due to receptor binding
2–3 hours (topical); 1–2 hours (systemic) after IV, with clinical duration prolonged due to tissue binding.
Renal (metabolites): ~75%; Fecal: ~25%
Primarily hepatic metabolism; metabolites excreted renally (70%) and in feces (30%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid